v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Revenues $ 3,923 $ 5,034
Cost of revenues 2,581 2,912
Gross profit 1,342 2,122
Operating expenses:    
Research and development, net 5,845 918
Sales and marketing 3,271 3,837
General and administrative 2,565 2,220
Total operating expenses 11,681 6,975
Operating loss (10,339) (4,853)
Financial expense (income), net [1] 448 (30)
Loss before income taxes (10,787) (4,823)
Taxes on income 6 11
Net loss $ (10,793) $ (4,834)
Net loss per ordinary share, basic $ (6.7) $ (5.53)
Net loss per ordinary share, diluted $ (6.7) $ (5.53)
Weighted average number of shares used in computing net loss per ordinary share, basic [2] 1,610,969 873,845
Weighted average number of shares used in computing net loss per ordinary share, diluted [2] 1,610,969 873,845
[1] Includes net financing expense comprised of interest expense and changes in fair value of warrant and derivative liabilities related to Oramed Pharmaceuticals Inc., a related party, of $416 for the three months ended March 31, 2026.
[2] Balance relates entirely to a related party arrangement with Oramed Pharmaceuticals Inc.